FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:658-665 August 14, 2003 Number 7 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Methotrexate and cyclosporine are well-known systemic therapies for moderate-to-severe chronic plaque psoriasis. We conduced a randomized, controlled trial comparing methotrexate and cyclosporine in terms of effectiveness, side effects, and the quality of life.

Methods A total of 88 patients with moderate-to-severe psoriasis were randomly assigned to treatment for 16 weeks with either methotrexate (44 patients; initial dose, 15 mg per week) or cyclosporine (44 patients; initial dose, 3 mg per kilogram of body weight per day) and were followed for another 36 weeks. The primary outcome was the difference between groups in the psoriasis area-and-severity index after 16 weeks of treatment, after adjustment for base-line values; scores were determined in a blinded fashion by trained observers.

Results Two patients were excluded from the analysis after randomization because they were found to be ineligible, and one patient withdrew his consent. Twelve patients in the methotrexate group had to discontinue treatment because of reversible elevations in liver-enzyme levels, and 1 patient in the cyclosporine group had to do so because of an elevation in the bilirubin level, but all 13 were included in the analysis. After 16 weeks of treatment, the mean (±SE) score for the psoriasis area-and-severity index decreased from 13.4±3.6 at base line to 5.0±0.7 among 43 patients treated with methotrexate, whereas the score decreased from 14.0±6.6 to 3.8±0.5 among 42 patients treated with cyclosporine. After adjustment for base-line values, the mean absolute difference in values at 16 weeks was 1.3 (95 percent confidence interval, –0.2 to 2.8; P=0.09). The physician's global assessment of the extent of psoriasis, the time to and the rates of remission, and the quality of life were similar in the two groups.

Conclusions No significant differences in efficacy were found between methotrexate and cyclosporine for the treatment of moderate-to-severe psoriasis.

Source Information

From the Departments of Dermatology (V.M.R.H., P.I.S., W.F.M.G., J.D.B., M.A.R.) and Clinical Epidemiology and Biostatistics (B.C.O., C.A.J.M.B., J.B.R., P.M.M.B.), Academic Medical Center, University of Amsterdam, Amsterdam.

Address reprint requests to Dr. de Rie at the Department of Dermatology, Rm. A0-222, Academic Medical Center, University of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, the Netherlands.

Full Text of this Article

This article has been cited by other articles:

• MacDonald, A, Burden, A D (2007). Psoriasis: advances in pathophysiology and management. Postgrad. Med. J. 83: 690-697 [Abstract] [Full Text]  
• Gelfand, J. M. (2007). Long-term Treatment for Severe Psoriasis: We're Halfway There, With a Long Way to Go. Arch Dermatol 143: 1191-1193 [Full Text]  
• Stern, R. S. (2007). Psoralen and Ultraviolet A Light Therapy for Psoriasis. NEJM 357: 682-690 [Full Text]  
• Schiener, R., Brockow, T., Franke, A., Salzer, B., Peter, R. U., Resch, K. L. (2007). Bath PUVA and Saltwater Baths Followed by UV-B Phototherapy as Treatments for Psoriasis: A Randomized Controlled Trial. Arch Dermatol 143: 586-596 [Abstract] [Full Text]  
• Smith, C. H, Barker, J N W N (2006). Psoriasis and its management. BMJ 333: 380-384 [Full Text]  
• (2006). New drugs for peripheral joint psoriatic arthritis. DTB 44: 1-5 [Abstract] [Full Text]  
• Nikas, S N, Voulgari, P V, Takalou, I P, Katsimbri, P, Drosos, A A (2005). Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment. Ann Rheum Dis 64: 1665-1667 [Full Text]  
• Yozai, K., Shikata, K., Sasaki, M., Tone, A., Ohga, S., Usui, H., Okada, S., Wada, J., Nagase, R., Ogawa, D., Shikata, Y., Makino, H. (2005). Methotrexate Prevents Renal Injury in Experimental Diabetic Rats via Anti-Inflammatory Actions. J. Am. Soc. Nephrol. 16: 3326-3338 [Abstract] [Full Text]  
• Madariaga, M. G., Naldi, L., Chatenoud, L., Khan, S., Schon, M. P., Boehncke, W.-H. (2005). Psoriasis. NEJM 353: 848-850 [Full Text]  
• Waters, V., Sokol, S., Reddy, B., Soong, G., Chun, J., Prince, A. (2005). The Effect of Cyclosporin A on Airway Cell Proinflammatory Signaling and Pneumonia. Am. J. Respir. Cell Mol. Bio. 33: 138-144 [Abstract] [Full Text]  
• Navarro-Martinez, M. D., Navarro-Peran, E., Cabezas-Herrera, J., Ruiz-Gomez, J., Garcia-Canovas, F., Rodriguez-Lopez, J. N. (2005). Antifolate Activity of Epigallocatechin Gallate against Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 49: 2914-2920 [Abstract] [Full Text]  
• Fraser, A D, van Kuijk, A W R, Westhovens, R, Karim, Z, Wakefield, R, Gerards, A H, Landewe, R, Steinfeld, S D, Emery, P, Dijkmans, B A C, Veale, D J (2005). A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 64: 859-864 [Abstract] [Full Text]  
• Schön, M. P., Boehncke, W.-H. (2005). Psoriasis. NEJM 352: 1899-1912 [Full Text]  
• Navarro-Peran, E., Cabezas-Herrera, J., Garcia-Canovas, F., Durrant, M. C., Thorneley, R. N.F., Rodriguez-Lopez, J. N. (2005). The Antifolate Activity of Tea Catechins. Cancer Res. 65: 2059-2064 [Abstract] [Full Text]  
• Nijsten, T., Rolstad, T., Feldman, S. R., Stern, R. S. (2005). Members of the National Psoriasis Foundation: More Extensive Disease and Better Informed About Treatment Options. Arch Dermatol 141: 19-26 [Abstract] [Full Text]  
• Heydendael, V. M. R., Spuls, P. I., Bossuyt, P. M. M., Bos, J. D., de Rie, M. A. (2004). Analysis of Risk Factors in Psoriatic Patients With Methotrexate-Induced Increases in Transaminase Levels. Arch Dermatol 140: 1289-1290 [Full Text]  
• Opmeer, B. C., Heydendael, V. M. R., de Borgie, C. A. J. M., Spuls, P. I., Bossuyt, P. M. M., Bos, J. D., de Rie, M. A. (2004). Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis: Economic Analysis in a Randomized Controlled Comparison of Methotrexate and Cyclosporine. Arch Dermatol 140: 685-690 [Abstract] [Full Text]  
• Stern, R. S. (2003). A Promising Step Forward in Psoriasis Therapy. JAMA 290: 3133-3135 [Full Text]  
• Lebwohl, M., Tyring, S. K., Hamilton, T. K., Toth, D., Glazer, S., Tawfik, N. H., Walicke, P., Dummer, W., Wang, X., Garovoy, M. R., Pariser, D., the Efalizumab Study Group, (2003). A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis. NEJM 349: 2004-2013 [Abstract] [Full Text]  
• (2003). Methotrexate and Cyclosporine Equally Effective for Chronic Plaque Psoriasis. Journal Watch Dermatology 2003: 3-3 [Full Text]